Skip to main content

Eurofins Viracor: 2023 Year in Review

As 2023 draws to a close, Eurofins Viracor, a leading infectious disease testing laboratory, takes a moment to reflect on the significant milestones and advancements achieved throughout the year. With a commitment to delivering cutting-edge diagnostic solutions, Eurofins Viracor has continued to push the boundaries of infectious disease testing, offering healthcare providers and patients access to innovative assays that enhance patient care and improve clinical outcomes.


New Assays Launched in 2023


In 2023, Eurofins Viracor introduced several groundbreaking assays that have expanded the company's testing capabilities and reinforced its position as a pioneer in infectious disease diagnostics. These assays include:


  • ExPeCT CAR T: Eurofins Viracor launched the ExPeCT CAR T assay, a highly specialized test designed to support the management of patients undergoing chimeric antigen receptor (CAR) T-cell therapy. This innovative assay provides valuable insights into the immune status of patients receiving CAR T-cell therapy, enabling healthcare providers to monitor and optimize treatment strategies while mitigating the risk of adverse events.


  • NTM (Non-Tuberculous Mycobacteria): The NTM assay represents a significant advancement in the detection and characterization of non-tuberculous mycobacterial infections. By leveraging state-of-the-art molecular techniques, Eurofins Viracor's NTM assay delivers rapid and accurate identification of NTM species, facilitating timely diagnosis and tailored treatment plans for patients affected by these challenging infections.


  • TA-TMA (Transplant-Associated Thrombotic Microangiopathy): Eurofins Viracor's TA-TMA assay addresses an unmet need in the field of transplant medicine by providing comprehensive testing for transplant-associated thrombotic microangiopathy. This assay enables the early detection and monitoring of TA-TMA in transplant recipients, supporting clinicians in assessing the risk of this serious complication and guiding therapeutic interventions to improve patient outcomes.


  • Candida auris: Recognizing the growing threat of Candida auris, an emerging multidrug-resistant fungal pathogen, Eurofins Viracor developed a specialized assay for the rapid detection and identification of this resilient organism. The Candida auris assay empowers healthcare providers with the tools to swiftly diagnose infections, implement infection control measures, and inform targeted antifungal therapy, thereby addressing the urgent need for effective management of this concerning pathogen.


Continued Commitment to Excellence


The launch of these new assays exemplifies Eurofins Viracor's unwavering commitment to advancing the field of infectious disease diagnostics and meeting the evolving needs of healthcare professionals and their patients. By harnessing the latest technologies and scientific expertise, Eurofins Viracor continues to deliver high-quality, clinically relevant testing solutions that have a meaningful impact on patient care across a broad spectrum of infectious diseases.


Looking Ahead


As Eurofins Viracor looks ahead to 2024, the company remains dedicated to driving innovation, expanding its test menu, and furthering its contributions to the field of infectious disease diagnostics. By staying at the forefront of scientific and technological developments, Eurofins Viracor is poised to continue shaping the future of infectious disease testing, ultimately improving outcomes for patients worldwide.


In conclusion, 2023 has been a year of achievement and progress for Eurofins Viracor, marked by the introduction of groundbreaking assays and the unwavering pursuit of excellence


About the author


Back to top